|Bid||12.53 x 2900|
|Ask||17.98 x 800|
|Day's Range||15.05 - 16.82|
|52 Week Range||11.00 - 26.74|
|Beta (3Y Monthly)||-0.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 24, 2019 - Apr 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.06|
Kamada (KMDA) wins the FDA acceptance for the path forward regarding its inhaled Alpha-1-Antitrypsin product, currently under development for treating Alpha-1 Antitrypsin Deficiency.
Fibrocell (FCSC) collaborates with Castle Creek to develop/commercialize its gene therapy candidate, FCX-007, for the rare skin disease of recessive dystrophic epidermolysis bullosa. Stock jumps.
Mallinckrodt (MNK) ends enrollment in the phase III study on StrataGraft, a regenerative skin tissue used in patients with thermal burns.
UTRECHT, The Netherlands, April 03, 2019 -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®,.
Merus N.V. (MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, and in collaboration with Incyte (INCY), presented preclinical data from the MCLA-145 program at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, GA. Merus and Incyte presented two posters outlining preclinical data on MCLA-145, the Biclonics® program targeting CD137 and PD-L1, on Sunday, March 31.
UTRECHT, Netherlands, March 11, 2019 -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®,.
UTRECHT, Netherlands, Feb. 07, 2019 -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific.
Vertex (VRTX) gains a nod from Health Canada for Kalydeco to treat cystic fibrosis (CF) in children aged 12 to less than 24 months.
Amarin (AMRN) reports preliminary results for 2018 and issues guidance for 2019. While the results exceeded estimates, outlook missed the same.
“We are pleased to announce the IND authorization to proceed from the FDA and to disclose more details around our latest Biclonics® program today,” said Andres Sirulnik, M.D., Ph. D., Executive Vice President and Chief Medical Officer of Merus. “Our preclinical work has demonstrated that MCLA-145 has the potential to overcome the known side effects of CD137 agonists currently in development and to address a significant unmet need in patient populations not benefitting from current immunotherapeutic agents. Discovered through an unbiased functional screening of multiple immunomodulatory target combinations, MCLA-145 is a Biclonics® T-cell agonist that binds with high affinity and specificity to human PD-L1 and CD137 in preclinical models.
Merus to retain all global rights outside of ChinaBetta Pharmaceuticals to fund global IND-enabling activities UTRECHT, the Netherlands, Jan. 02, 2019 -- Merus N.V. (Nasdaq:.
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stocks hit a 52-week peak Thursday. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. 27) • Aevi ...
Clinical milestones for four lead Biclonics® programs expected in 2019Cash expected to be sufficient to fund operations into the second quarter of 2021 UTRECHT, The.
Merus N.V. (MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced a settlement of all pending patent litigation and administrative proceedings between Merus and Regeneron Pharmaceuticals, Inc. pertaining to certain antibody generation platforms of each company. As part of the settlement, both parties have signed a global patent cross-license agreement, and Regeneron has agreed to provide an investment in Merus of $15 million through the purchase of 600,000 common shares at a price of $25 per share representing a premium of 118% from the close of trading on December 20, 2018.
Does Merus N.V. (NASDAQ:MRUS) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on research activities, so it is no wonder why they tend to generate millions in profits […]
Merus NV (NASDAQ:MRUS), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is MRUS will Read More...
Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UTRECHT, The Netherlands, Nov. 08, 2018 -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics.